Critical Care

official impact factor 4.60
Search for
Advanced search
Critical Care
Tools
Highly Access Letter

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death

Mark D Williams*, Jonathan M Janes and David R Nelson

Author Affiliations

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA

For all author emails, please log on.

Critical Care 2006, 10:424 doi:10.1186/cc5062

Published: 30 October 2006

First paragraph (this article has no abstract)

We read with interest the recent commentary by Friedrich and colleagues [1] that reported a meta-analysis of the two placebo-controlled clinical trials of Drotrecogin alfa (activated) (Drot Aa): the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation of Severe Sepsis) [2] and ADDRESS (Administration of Drotrecogin Alfa [Activated] in Early Stage Severe Sepsis) [3] trials. Several methodological concerns in the analysis by Friedrich and colleagues severely limit the utility of the analysis and call into question the conclusions.